Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Phase 1 Completed 20 enrolled Bial - Portela C S.A.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined oral contraceptive (ethinyloestradiol and levonorgestrel).

Timeline

Start: 2008-09
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eslicarbazepine acetate	Unknown	800 mg	Oral
Subject	Microginon®	Unknown	—	Oral

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Summary

Timeline

Drugs

Indications